Trump's 'World's Lowest Drug Prices' Claim Doesn't Hold Up

The claim that Americans now pay the "lowest prices in the world" is contradicted by the evidence fact-checkers have compiled. A RAND Corporation analysis of 2022 data found U.S. drug prices average 2.78 times higher than in other developed countries, and 4.22 times higher for brand-name drugs before manufacturer discounts. ^[1]

An analysis by drug-pricing research firm 46brooklyn found that drug companies — including all 16 that signed voluntary MFN deals with the Trump administration — raised the list prices of 872 brand-name drugs in the first two weeks of January 2026, at a median increase of 4%, identical to the median increase in 2025. ^[2]

46brooklyn CEO Antonio Ciaccia said of the deals: "The real truth serum is what's happening in the marketplace after those deals occur," adding that the 2026 increases are "pretty much in line with the last few years." ^[2]

TrumpRx.gov advertises "the cheapest prices in the world" on 43 brand-name drugs, but an independent STAT News analysis found at least 18 of them have cheaper generic alternatives available through GoodRx or Mark Cuban's Cost Plus Drugs. ^[3]

For example, TrumpRx lists Protonix at $200 for a 30-pack, while the generic version costs about $6 on Cost Plus Drugs. TrumpRx prices Cetrotide at $22.50 — far below GoodRx's $309 list price, but still above the roughly $49.50 generic price on Cost Plus Drugs. ^[3]

Georgetown health policy researcher Yunan Ji noted the discounts apply only to cash-paying patients: "The prices are absolutely cheaper than list prices, but only for cash patients" or those "whose insurance does not sufficiently cover these drugs," and purchases don't count toward insurance deductibles. ^[4]

Cutting a drug's price by 100% would make it free; cutting it by more than 100% is mathematically impossible, since it would require drug companies to pay customers to take their product. ^[5][6]

Trump has nonetheless repeatedly claimed cuts beyond that threshold, saying at one point, "No, we're gonna get them down 1,000%, 600%, 500%, 1,500%," and in a December prime-time address that prices would fall "400 to 600%." ^[5][7]

Timothy McBride, a health economist at Washington University in St. Louis, called the claims "just not logical," explaining that a 500% cut would turn a $100 drug into one priced at negative $400 — he said he knows "of no drug company in the world that would give a person $400 to buy a drug that they are now pricing at $100." ^[5]

Geoffrey Joyce, director of health policy at USC's Schaeffer Center, separately called a 1,500% price-cut claim "total fiction," telling fact-checkers there has been no sign of a cut anywhere close to that size. ^[6]

On Fox News on December 18, 2025, host John Roberts pressed Commerce Secretary Howard Lutnick on the math: "If you cut it by 4-, 5-, 600 percent, the drug companies are actually paying you to take their product." Lutnick responded that a drop from $100 to $13 could be framed as either an 87% cut or, in reverse, a 700% increase — "it just depends on the way you look at it." ^[7]

The most significant drug price reductions taking effect in 2026 come from the Biden-era Inflation Reduction Act's Medicare drug price negotiation program, not Trump's voluntary MFN deals. Under IRA negotiations, a 30-day supply of Januvia will cost $113 in 2026, down 79% from its 2023 list price of $527, and Eliquis will cost $231, a 56% reduction from its 2023 price of $521. ^[8]

KFF health policy analyst Juliette Cubanski noted that the Trump administration "can take credit for delivering lower drug prices in Medicare," while Democrats "can take credit for creating the Medicare drug price negotiation program" in the first place. ^[9]

Separately, the Congressional Budget Office reported in November 2025 that private insurance plans administering Medicare Part D submitted bids anticipating a 35% increase in per-enrollee costs for 2026 — far above the 5% increase CBO had projected before the bids came in, following a 42% jump from 2024 to 2025. ^[10]

If insurers' higher cost expectations hold, CBO estimates Medicare Part D spending over the next decade could run about $500 billion more than previously projected — a sign that pricing pressure in the program remains largely unresolved regardless of MFN deals or TrumpRx. ^[10]

President Trump's claim that Americans are "now paying the lowest price anywhere in the world for drugs" is false. U.S. drug prices remain roughly 2.78 times higher than peer nations on average, and all 16 companies that signed MFN deals with the administration still raised list prices on hundreds of drugs in January 2026. ^[1][2]

TrumpRx.gov offers real, if narrow, cash-pay discounts on 43 brand-name drugs, but independent analysis found cheaper generic alternatives for at least 18 of them, and the savings don't reach insured patients or count toward deductibles. ^[3][4]

Trump's claims of cutting prices by "400 to 600%" or "1,200 to 1,500%" are mathematically impossible, as multiple health economists — and a Fox News anchor, on air — have pointed out. ^[5][6][7]

The most substantial 2026 drug price cuts came from the Biden administration's Inflation Reduction Act negotiations, not from Trump's voluntary deals — an inconvenient detail missing from the "world's lowest prices" claim. ^[8][9]